79583-19-0Relevant academic research and scientific papers
Synthesis and apoptotic activity of new pyrazole derivatives in cancer cell lines
Nitulescu, George Mihai,Draghici, Constantin,Olaru, Octavian Tudorel,Matei, Lilia,Ioana, Aldea,Dragu, Laura Denisa,Bleotu, Coralia
, p. 5799 - 5808 (2015)
We designed and synthesized new pyrazole thiourea chimeric derivatives and confirmed their structures by NMR and IR spectra. Apoptotic effects were studied in human cancer cells. The N-[(1-methyl-1H-pyrazol-4-yl)carbonyl]-N′-(3-bromophenyl)-thiourea compo
Design, synthesis and biological evaluation of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors
Wang, Xing-Rong,Wang, Shuai,Li, Wen-Bo,Xu, Kai-Yan,Qiao, Xue-Peng,Jing, Xue-Li,Wang, Zi-Xiao,Yang, Chang-jiang,Chen, Shi-Wu
supporting information, (2021/01/26)
Vascular endothelial growth factor-2 (VEGFR-2) plays a pivotal role in tumor angiogenesis. Herein, a library of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol -1-yl)acetamide derivatives were designed and synthesized as VEGFR-2 inhibitors based on scaffold hopping strategy. These compounds exhibited the excellent inhibitory in both VEGFR-2 and tumor cells proliferation. Especially, compound W13 possessed potent VEGFR-2 inhibition with IC50 = 1.6 nM and anti-proliferation against HGC-27 tumor cells with IC50 = 0.36 ± 0.11 μM, as well as less toxicity against normal GES-1 cells with IC50 = 187.46 ± 10.13 μM. Moreover, W13 obviously inhibited colony formation, migration and invasion of HGC-27 cells by adjusting the expression of MMP-9 and E-cadherin, and induced HGC-27 cells apoptosis by increasing ROS production and regulating the expression of apoptotic proteins. Furthermore, W13 blocked the PI3K-Akt-mTOR signaling pathway in HGC-27 cells. In addition, anti-angiogenesis of W13 was proved by inhibiting tube formation and the expression of p-VEGFR-2 in HUVEC cells. All the results demonstrated that W13 could be developing as a promising anticancer agent for gastric cancer therapy.
POLYMORPHS OF (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE
-
Paragraph 0161-0162, (2021/02/12)
Provided herein are polymorphs of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, compositions thereof, methods of preparation thereof, and methods of their uses.
Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
Ashcraft, Luke,Chin, Eva R.,Chuang, Chihyuan,Collibee, Scott,Cremin, Peadar,Hartman, James,Hwee, Darren T.,Malik, Fady I.,Morgan, Bradley P.,Robertson, Laura A.,Schaletzky, Julia,Vander Wal, Mark,Wang, Jingying,Wang, Wenyue,Wang, Xiaolin,Wehri, Eddie,Wu, Yangsong,Zamora, Jeanelle
supporting information, p. 14142 - 14152 (2021/10/20)
Hypercontractility of the cardiac sarcomere may be essential for the underlying pathological hypertrophy and fibrosis in genetic hypertrophic cardiomyopathies. Aficamten (CK-274) is a novel cardiac myosin inhibitor that was discovered from the optimization of indoline compound 1. The important advancement of the optimization was discovery of an Indane analogue (12) with a less restrictive structure-activity relationship that allowed for the rapid improvement of drug-like properties. Aficamten was designed to provide a predicted human half-life (t1/2) appropriate for once a day (qd) dosing, to reach steady state within two weeks, to have no substantial cytochrome P450 induction or inhibition, and to have a wide therapeutic window in vivo with a clear pharmacokinetic/pharmacodynamic relationship. In a phase I clinical trial, aficamten demonstrated a human t1/2 similar to predictions and was able to reach steady state concentration within the desired two-week window.
NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVES, AND USES THEREOF
-
Paragraph 0064, (2020/12/10)
The present disclosure relates to a novel nucleoside or nucleotide derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating viral infection-associated diseases, containing the same as an active ingredient.
Synthesis and antifungal activity of carvacrol and thymol esters with heteroaromatic carboxylic acids
Fan, Liming,Jiang, Shanshan,Su, Fawu,Wang, Kaibo,Yang, Yunhai,Ye, Min
, p. 1924 - 1930 (2018/06/11)
Aiming to obtain the more effective pathogen inhibitive ingredients and explore the influence of introducing different heterocyclic units to carvacrol and thymol esters, twenty ester derivatives with different heterocyclic units were synthesized. And the
NAPHTHYRIDINES AS INHIBITORS OF HPK1
-
Paragraph 1066; 1067, (2018/10/21)
Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE
-
Paragraph 00400, (2016/09/22)
The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(5-[5-[(1H4ndazol-5-yl)amino]-1,3,4-thiadiazol-2-yl]pyridin-3-yl)acetamide compound.
Pyrazole ketone compound or its salt, preparation method thereof, and use of the herbicide composition (by machine translation)
-
Paragraph 0133; 0134; 0135, (2016/10/08)
This application pertains to the field of agricultural chemicals, in particular to a pyrazole ketone compound or its salt, preparation method, herbicidal composition and use. The ketone compounds states the pyrazole shown as formula I: In the formula, R 1 R 2 N representative containing substituted or unsubstituted 1-3 of the aza-3-8-membered nitrogen-containing heterocyclic base; or R 1, R 2 respectively represents hydrogen, C 1-8 alkyl etc.; R 3 representative hydrogen, C 1-4 alkyl, alkenyl, alkynyl, or unsubstituted C 1-4 alkyl substituted C 3-6 cycloalkyl; R 4 represents methyl, ethyl, n-propyl, isopropyl, cyclopropyl; X represents hydrogen, -S (O) n R 6, -R 7, containing substituted or unsubstituted 1-4 of the aza-3-8-membered heterocyclic group, wherein n representative 1, 2, 3, R 6 represents a substituted or unsubstituted alkyl or aryl, R 7 represents a substituted or unsubstituted alkyl, aryl, alkanoyl or sweet-smelling acyl. The present invention provides good efficacy of the pharmaceutical actives, easy to use, low cost, has good commercial value. (by machine translation)
Nickel(II)-Mediated Regioselective C H Monoiodination of Arenes and Heteroarenes by using Molecular Iodine
Khan, Bhuttu,Kant, Ruchir,Koley, Dipankar
supporting information, p. 2352 - 2358 (2016/07/28)
The 8-aminoquinoline-directed, nickel(II)-mediated ortho-iodination of benzamides using molecular iodine has been developed. The process is highly regioselective and furnishes only monoiodinated products. A broad range of arenes and heteroarenes with diverse functional groups provided monoiodinated products in good to excellent yields. (Figure presented.) .
